Navigation Links
Delcath Systems Announces the Sale of 5,185,000 Shares of Common Stock
Date:8/16/2010

NEW YORK, Aug. 16 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company"), today announced the sale of 5,185,000 shares of its common stock pursuant to an underwriting agreement with Canaccord Genuity acting as the sole bookrunner.  The last reported sale price of the Company's common stock as reported by the Nasdaq Capital Market on August 16, 2010 was $7.15 per share.

The Company expects to use the net proceeds from the sale of the shares for funding of its clinical trials, research and development, obtaining regulatory approvals, manufacturing, operations, sales, commercialization of its products and other general corporate purposes, including capital expenditures and working capital.  Closing of the offering is expected to occur on or about August 20, 2010, subject to customary closing conditions.  In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 777,750 shares of common stock to cover over-allotments, if any.

The offering is being made pursuant to an effective shelf registration statement.  Before you invest, you should read the base prospectus in such shelf registration statement, the prospectus supplement, when available, and other documents the Company has filed with the Securities and Exchange Commission for more complete information about the Company and this offering.  The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to the offices of Canaccord Genuity, Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, phone: (800) 225-6201.  Alternatively, you may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Delcath Systems

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology.  Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents.  The Company's initial focus is on the treatment of primary and metastatic liver cancers.  Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system.  For more information, please visit the Company's website at www.delcath.com.  

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug-delivery system for the treatment of other liver cancers and other organs, the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, actions by the FDA or other regulatory agencies, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets,  and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Delcath Highlights Phase III Trial Results Presented at ASCO
2. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
3. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
4. Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
5. Delcath Enters Agreement to Sell 869,565 Units
6. Delcath Systems Granted Third Orphan Drug Designation
7. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
8. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
9. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
10. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
11. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer diagnostics ... in booth B2 at the Association for Pathology Informatics Annual Summit ... addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present ...
(Date:5/21/2017)... , ... May 20, 2017 , ... ... helps avoid the lengthy trial and error process by finding the right antidepressant ... can also strengthen the doctor-patient relationship through a personalized approach to treatment. ...
(Date:5/19/2017)... ... May 19, 2017 , ... The ... Academic researchers with technologies ripe for commercialization, and who are affiliated with the ... encouraged to submit proposals. QED, now in its tenth round, is the first ...
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u ... Cooking Challenge is a two-hour team-building package designed for groups of 10-30 people. ... Jodi Abel, which include items, such as Blackened Shrimp with Edamame Salad, Pizza ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market ... the next decade to reach approximately $14.21 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:3/22/2017)... NEW YORK , March 21, 2017 /PRNewswire/ ... Customer Marketing Cloud used by retailers such as ... in its platform — Product Recommendations and Replenishment. Using ... to give more personalized product and replenishment recommendations ... purchases, but also on predictions of customer intent ...
Breaking Biology News(10 mins):